Combination treatment for advanced colorectal cancer after prior therapy
Treatments studied
Part of Cancer, Digestive system clinical trials.
This study tests a new combination of two drugs, aipalirovorelizumab and fruquintinib, for people with a specific type of advanced colorectal cancer that has not responded to earlier treatments. The goal is to see if this combination can help control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have advanced or metastatic colorectal cancer that is MSS (a type that doesn't have certain high mutation markers).
- Your tumor has at least one specific positive immune marker (like PD-L1 or TMB).
- You have already tried at least two previous treatments, or one if you cannot tolerate the standard second treatment.
- Your overall health is good (able to do light activity, life expectancy at least 3 months).
- You can provide a stored tumor sample for testing.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs and a liver-directed therapy for people with advanced colorectal cancer that has spread to the liver. It aims to see if this approach can help when standard first-line treatment has stopped working.
This trial tests a new combination of drugs (cadonilimab, fruquintinib) plus targeted radiation (SBRT) for people with advanced MSS colorectal cancer who have already tried several standard treatments. The goal is to see if this combination can help shrink tumors or slow disease progression.
This study tests a new combination of drugs (an immunotherapy called QL1706 plus bevacizumab and standard chemotherapy) as a first-line treatment for people with advanced colorectal cancer that has a BRAF V600E mutation. The goal is to see if this combination helps shrink tumors and improve outcomes.
This trial tests a new combination of two drugs (DSP107 and atezolizumab) compared to another drug (fruquintinib) for people with advanced colorectal cancer that hasn't responded to standard treatments. The goal is to find a more effective treatment option.
This trial is testing a new combination of two oral cancer drugs (fruquintinib and S-1) in people with metastatic colorectal cancer who have already had at least one prior chemotherapy. The goal is to see if this combination helps shrink or slow the growth of tumors.
This study tests a combination of an immunotherapy drug, a targeted therapy, and a type of low-dose radiation before standard third-line treatment in patients with colorectal cancer that has spread to the liver. The goal is to see if this approach is safe and helps shrink tumors or slow cancer growth.
Hear when a new Colorectal cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.